| Literature DB >> 34853360 |
Bénédicte Pérignon1, Octave Nadile Bandiaky2, Caroline Fromont-Colson1, Stéphane Renaudin1, Morgane Peré3, Zahi Badran4, Madline Cuny-Houchmand1, Assem Soueidan5.
Abstract
This prospective randomized clinical trial aimed to evaluate the effect of low-level laser therapy on tooth movement during Class II intermaxillary elastics treatment. Forty-two patients with Class II malocclusion were included, and their maxillary quadrants were allocated into two groups: treatment with an active diode laser and a placebo group. In each group, the time taken to obtain Class I occlusion after 6 months, rate of movement, total displacement of the maxillary canine to Class I occlusion and pain were recorded. The time to reach Class I occlusion in the active laser group (2.46 ± 2.1 months) was not significantly different from that in the placebo group (2.48 ± 2.0 months) (p = 0.938). Interestingly, the total distance of movement on the active laser side (2.27 ± 1.5 mm) was significantly greater than that on the placebo side (1.64 ± 1.3 mm) (p = 0.009). The pain levels on days 1, 2 and 3 were not significantly different between the laser and placebo sections. The rate of distance change toward Class I occlusion in the laser group (1.1 ± 0.7 mm/month) was significantly higher than that in the placebo group (0.74 ± 0.6 mm/month) (p = 0.037). Low-level laser therapy (970 nm) did not reduce the time needed to obtain Class I occlusion, but a significant acceleration in tooth movement was observed in the irradiated group.Trial registration: NCT02181439. Registered 04 July 2014- https://www.clinicaltrials.gov/ct2/results?term=cinelaser .Entities:
Mesh:
Year: 2021 PMID: 34853360 PMCID: PMC8636571 DOI: 10.1038/s41598-021-02610-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Vestibular laser application points.
Figure 2Example of the questionnaire measuring pain with a VAS.
Patient characteristics and mean distances between the maxillary and mandibular canine tips in the irradiated and placebo groups at baseline.
| Variables | Group A | Group B | Total | ||
|---|---|---|---|---|---|
| Age, Mean ± SD (Min–Max) | 14 ± 1.4 (12–16) | 13.1 ± 1.5 (10–16) | 13.6 ± 1.5 | ||
| Men | 5 (25%) | 8 (38.1%) | 13 (31.7%) | ||
| Women | 15 (75%) | 13 (61.9%) | 28 (68.3%) | ||
| Distance between the maxillary and mandibular canine tips on the right Mean (SD) | − 1 (1.6) | − 1 (1.6) | − 1. (1.6) | ||
| Distance between the maxillary and mandibular canine tips on the left Mean (SD) | − 1.6 (2) | − 1 (1.8) | − 1.2 (1.9) | ||
| Class II confirmed on right/left, n (%) | 20 (100%) | 21 (100%) | 41 (100%) |
mm millimeters, SD standard deviation, 95% CI 95% confidence interval; significant at p < .05.
Figure 3Flowchart of the study.
Mean time to reach canine Class I occlusion in Class II elastics patients in the two groups.
| Groups | Mean (month) | SD | 95% CI | ||
|---|---|---|---|---|---|
| Time to reach Class I occlusion in patients wearing Class II elastics | Laser (n = 41) | 2.46 | 2.1 | 1.8; 3.1 | 0.938 |
| Placebo (n = 41) | 2.48 | 2.0 | 1.8; 3.1 |
SD standard deviation, 95% CI 95% confidence interval; significant at p < .05.
Mean displacement of the maxillary canine to Class I in the two groups.
| Groups | Mean (mm) | SD | 95% CI | ||
|---|---|---|---|---|---|
| Total distance traveled by the maxillary canine to reach Class I | Laser (n = 27) | 2.27 | 1.5 | 1.7; 2.8 | 0.009* |
| Placebo (n = 27) | 1.64 | 1.3 | 1.1; 2.2 |
mm millimeters, SD standard deviation, 95% CI 95% confidence interval; *Indicates significant differences between the groups.
Mean differences in evaluation of the VAS scores at D1, D2 and D3 in the two groups.
| Mean of differences between the laser and placebo halves | SD of differences between the laser and placebo halves | 95% CI | |||
|---|---|---|---|---|---|
| VAS at D1 | 32 | − 0.2 | 2.5 | − 1.1; 0.7 | 0.600 |
| VAS at D2 | 32 | 0.1 | 2 | − 0.6; 0.8 | 0.795 |
| VAS at D3 | 31 | 0.2 | 1.8 | − 0.4; 0.9 | 0.477 |
VAS visual analog scale, D1 day 1, D2 day 2, D3 day 3, SD standard deviation; significant at p < .05.
Mean rate to reach Class I occlusion in the two groups.
| Groups | Mean (mm/month) | SD | 95% CI | ||
|---|---|---|---|---|---|
| Rate to reach Class I (intention-to-treat population) | Laser (n = 27) | 1.0 | 0.7 | 0.7; 1.3 | 0.037* |
| Placebo (n = 27) | 0.7 | 0.6 | 0.5; 1.0 |
mm millimeters, SD standard deviation, *Indicates significant changes between the groups.